41st week of 2011 patent applcation highlights part 41 |
Patent application number | Title | Published |
20110251127 | Inactivation of infectious agents in plasma proteins by extreme pressure - A method of inactivation of infectious agents in a fluid containing plasma protein and potentially containing at least one infection agent which includes unique steps of placing the fluid in a container which is resistant to leakage under high pressure, placing the container in a compression chamber, pressurizing the fluid inside the container to a pressure sufficient to inactivate the potential infectious agent, pressurizing the fluid under a high pressure for a time duration sufficient to inactivate the potential infectious agent and pressurizing the fluid under the high pressure at an initial temperature that does not inactivate coagulation factors under the conditions. The present invention also includes a fluid containing plasma proteins which is pressurized to inactivate infectious agents, the plasma proteins containing serum albumen and at least one coagulation factor. | 2011-10-13 |
20110251128 | THYMOSIN Beta4 PEPTIDES PROMOTE TISSUE REGENERATION - The present invention relates to thymosin β-4 peptides and analogs thereof that can promote tissues regeneration, particularly cardiac tissue. | 2011-10-13 |
20110251129 | RHEUMATOID ARTHRITIS-PREVENTIVE AGENT FOR ORAL INTAKE - There is provided a rheumatoid arthritis inhibitor for oral intake that has an inhibitory effect on rheumatoid arthritis and is excellent in safety. The rheumatoid arthritis inhibitor for oral intake of the present invention contains, as an active component, a casein hydrolysate containing free amino acids and peptides obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, or a mixture of free amino acids and peptides contained in the hydrolysate. | 2011-10-13 |
20110251130 | Methods and Compositions for Promoting Bone Growth - The invention relates to methods and compositions for promoting bone growth, bone healing and/or bone formation. Disclosed herein are isolated truncated Wilms tumor on gene chromosome X (WTX) polypeptides and uses thereof. Also disclosed are methods of treating a bone related disease or condition in a subject by modulating the expression or activity of a (WTX) polypeptide in bone cells of the subject. The bone related disease or condition is any disease or condition including bone related trauma or injury due to any cause including surgery. The compositions and methods according to the invention are useful for enhancing and stimulating bone mineralization and for preferentially directing the differentiation of certain stem cells, thereby altering cell fate. | 2011-10-13 |
20110251131 | DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES - This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist. | 2011-10-13 |
20110251132 | TREATMENT WITH A PHARMACEUTICAL COMPOSITION COMPRISING MANF2 NUCLEIC ACID - A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof. | 2011-10-13 |
20110251133 | Blockade of gamma-secretase activity to promote myelination by oligodendrocytes - Methods are provided for enhancing myelination. Myelination is enhanced by administration of agents that are inhibitors of γ-secretase. Methods of screening for pharmaceutically active compounds that enhance myelination, and for genes involved in myelination are also provided. | 2011-10-13 |
20110251134 | COMBINATION OF (A) A DNA TOPOSOMERASE INHIBITOR AND (B) AN IAP INHIBITOR - The invention relates to a pharmaceutical combination which comprises (a) a DNA topoisomerase inhibitor compound and (b) a compound that inhibits the caspase-9 inhibiting properties of an inhibitor of apoptosis protein (IAP) for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 2011-10-13 |
20110251135 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS - Disclosed compositions and methods for inhibiting NF-κB mediated cellular proliferation and metastasis. | 2011-10-13 |
20110251136 | GLUE COMPOSITION FOR LUNG VOLUME REDUCTION - The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. | 2011-10-13 |
20110251137 | GAMMA-POLYGLUTAMIC ACID-BASED OCULAR IRRIGATING SOLUTIONS - Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) γ-polyglutamic acid (γ-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution; and b) an ophthalmically acceptable aqueous vehicle for the γ-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising γ-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient. | 2011-10-13 |
20110251138 | LIPOIC ACID METABOLITE CONJUGATE: PREPARATION AND THEIR THERAPEUTIC EFFECT - The present invention is a design and synthesis of a series of therapeutic conjugates which consists of tautomers of lipoic acid metabolites, with small molecule, vitamin, carbohydrates, peptides, chemotherapeutic agent wherein or not the conjugate possesses dual binding ability. The present invention can be used to therapeutics and diagnostics in vitro for cancer and other diseases associated with altered metabolic enzymes. The invention can also be used for the controlled release of more stable form of lipoic acid in its salt form with the minerals or vitamins. | 2011-10-13 |
20110251139 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH MAMMAL BETA DEFENSINS - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 2011-10-13 |
20110251140 | PEPTIDE ANTAGONIST OF INTERLEUKIN-15 ACTIVITY - The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor α (TNFα) induction and the expression of IL-8 and IL-6 by the IL-15 receptor a subunit (IL-15Rα), all these effects mediated by the binding of the peptide to the IL-15Rα. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15Rα is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer. | 2011-10-13 |
20110251141 | COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS - A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection. | 2011-10-13 |
20110251142 | USE OF TRITERPENIC AND ANTHRAQUINONE GLYCOSIDES AS SUBSTANCES EXERTING HYDRAGOGUE ACTIVITY ON MUCOSA OF UPPER RESPIRATORY APPARATUS FOR THE TREATMENT OF THE EFFECTS RESULTING FROM THE UPPER RESPIRATORY TRACT DISEASES - Use of triterpene and anthraquinone glycosides, as substances exerting hydragogue activity on mucosa of upper respiratory apparatus, for the treatment of the effects resulting from the upper respiratory tract diseases. The present invention concerns the use of triterpene and anthraquinone glycosides, as substances exerting hydragogue activity on mucosa of upper respiratory apparatus, for the treatment of the effects resulting from the upper respiratory tract diseases as for example, sinusitis, both acute or chronic, rhinosinusitis, rhinitis. | 2011-10-13 |
20110251143 | STABLE ELSAMITRUCIN SALT FORMULATIONS - Formulations containing stable forms of elsamitrucin salts are provided. These formulations are useful for treating neoplastic diseases and conditions. | 2011-10-13 |
20110251144 | MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed. | 2011-10-13 |
20110251145 | Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause - The present invention relates to a pharmaceutical composition for preventing or treating a menopausal symptom, comprising cinnamic acid, shanzhiside methylester or a mixture thereof as an active ingredient. The composition of the present invention exhibits an excellent estrogenic activity, and is effectively utilized for treating or preventing diverse menopausal symptoms generated by estrogen deficiency during perimenopause, menopause and postmenopause. | 2011-10-13 |
20110251146 | TOPICAL ANTIFUNGAL COMPOSITION - A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition. | 2011-10-13 |
20110251147 | Compositions Comprising Quinolone and Methods for Treating or Controlling Infections - Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site. | 2011-10-13 |
20110251148 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV - Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof. | 2011-10-13 |
20110251149 | METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS - Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks. | 2011-10-13 |
20110251150 | Targeting MicroRNAs For The Treatment Of Liver Cancer - Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis. | 2011-10-13 |
20110251151 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE - Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A | 2011-10-13 |
20110251152 | NUCLEOSIDE PHOSPHORAMIDATES - Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. | 2011-10-13 |
20110251153 | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR HEMOGLOBINURIA OR MYOGLOBINURIA - A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided. | 2011-10-13 |
20110251154 | SULFATED POLYSACCHARIDE COMPOUND AND THE PREPARATION AND USE THEREOF - The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use. | 2011-10-13 |
20110251155 | Methods of Using Diacerein as an Adjunctive Therapy for Diabetes - The present invention provides methods of treating type II diabetes using combinations of diacerein or its derivatives with other antidiabetic agents. The methods may also allow improving glycemic control of type II diabetes patients and/or reducing side effects and/or cardiovascular risks of antidiabetic agents. | 2011-10-13 |
20110251156 | VEHICLE FOR DELIVERING A COMPOUND TO A MUCOUS MEMBRANE AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases. | 2011-10-13 |
20110251157 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid - An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. | 2011-10-13 |
20110251158 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE - Described herein are methods for treating inflammatory disorders or for inhibiting the build-up of arterial plaque. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene. | 2011-10-13 |
20110251159 | Phosphoramidate Alkylator Prodrugs - Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents. | 2011-10-13 |
20110251160 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 2011-10-13 |
20110251161 | PERSONAL CARE COMPOSITION - A personal care composition comprising a eutectic mixture, the eutectic mixture comprising an alkyl monoethanolamide having an alky chain length from 10 to 14. | 2011-10-13 |
20110251162 | METHODS OF TREATMENT FOR MRSA INFECTIONS - The present subject matter relates to pathogenesis of MRSA. Specifically, the present disclosures identifies the pro-inflammatory properties of PVL as the cause of MRSA. Viewed from this new perspective, the present subject matter achieves novel methods and apparatus for treating MRSA infection in a subject involving the administration of an anti-inflammatory drug to the subject. Furthermore the present subject matter teaches methods and apparatus for treating a Panton-Valetine leukocidin associated infection in a subject involving the administration of an anti-inflammatory drug to the subject. | 2011-10-13 |
20110251163 | Transdermal Delivery - Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval. | 2011-10-13 |
20110251164 | Carboxamide Derivatives As Muscarinic Receptor Antagonists - The invention relates to compounds of formula | 2011-10-13 |
20110251165 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR - The present invention provides a compound of formula (I) wherein: R | 2011-10-13 |
20110251166 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR - The present invention provides a compound of formula (I) wherein: R | 2011-10-13 |
20110251167 | ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME - A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided. | 2011-10-13 |
20110251168 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS - The present invention relates to 3-aminopyrrolidine derivatives of the formula I: | 2011-10-13 |
20110251169 | Arylethynyl derivatives - The present invention relates to ethynyl compounds of formula I | 2011-10-13 |
20110251170 | NEW POLYMORPHIC FORM OF 1-(4--2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC - This invention relates to a novel crystalline form (Form A) of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this crystalline form, to processes for forming it and to its use in medical treatment. | 2011-10-13 |
20110251171 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE - Compounds of the formula | 2011-10-13 |
20110251172 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE - The invention encompasses purine derivatives as gamma secretase modulators, useful for treating diseases associated with the deposition of beta-amyloid peptide in the brain, such as Alzheimer's disease, or of preventing or delaying the onset of dementia associated with such diseases. Pharmaceutical compositions and methods of use are included. | 2011-10-13 |
20110251173 | CHEMICAL COMPOUNDS - DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity | 2011-10-13 |
20110251174 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS - The present invention encompasses compounds of general formula (1) | 2011-10-13 |
20110251175 | Stigmine Conjugates for Substance Use Disorders - The invention relates to methods for the treatment or prevention of substance use disorders. | 2011-10-13 |
20110251176 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2011-10-13 |
20110251177 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES - The present disclosure provides biologically active 2,4-pyrimidinediamine compounds of formulae (I) and (II): | 2011-10-13 |
20110251178 | Bicyclic Pyridinylpyrazoles - Bicyclic pyridinylpyrazoles of the formula (I) | 2011-10-13 |
20110251179 | 3,4-DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES - Compounds which are 4,7-disubstituted derivatives of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds, or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them. | 2011-10-13 |
20110251180 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND - The present invention provides a pharmaceutical agent that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the pharmaceutical agent of the invention comprising as an active ingredient a quinolone compound represented by Formula (1): | 2011-10-13 |
20110251181 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS - Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I). | 2011-10-13 |
20110251182 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES - This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity. | 2011-10-13 |
20110251183 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES - The present invention is concerned with aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula I | 2011-10-13 |
20110251184 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 2011-10-13 |
20110251185 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS - The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: | 2011-10-13 |
20110251186 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I | 2011-10-13 |
20110251187 | HETEROCYCLIC COMPOUND - The present invention relates to a compound represented by | 2011-10-13 |
20110251188 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF - The present invention relates to acenaphtho heterocyclic compounds, cyclodextrin inclusion compounds and complexes thereof, and their uses in manufacturing the inhibitors of BH3 analogue, Bcl-2 family proteins. The acenaphtho heterocyclic compounds are obtained by introducing oxo-, thio-, carbonyl, ester or acyl in the 3-, 4- and 6-position of 8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile, or further substituting 9-cyano with carboxyl, ester or amide. The compounds can simulate BH3-only protein, competitively binding and antagonizing Bcl-2, Bel-X | 2011-10-13 |
20110251189 | HYPOXIA TARGETED COMPOUNDS FOR CANCER DIAGNOSIS AND THERAPY - The present invention generally relates to oxazine derivative compounds and related compositions and methods for inducing hypoxic tumor cell death, treating cancer and locating a hypoxic tumor in a subject. | 2011-10-13 |
20110251190 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I | 2011-10-13 |
20110251191 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA - The present invention relates to the use of 2,3-dihydroimidazo[1,2-c]quinazoline compounds, and of pharmaceutical compositions containing such compounds, for the treatment or prophylaxis of multiple myeloma, as a sole agent or in combination with other one or more other active ingredients. | 2011-10-13 |
20110251192 | AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR PREPARATION METHOD AND THEIR USES - The present invention pertains to the field of pharmaceutical chemistry and discloses 8-(3-aminopropyl)-3-exo-8-azabicyclo[3.2.1]octane-3-amino amide compounds represented by formula I, the pharmaceutical compositions, the preparation method and the use thereof. Such compounds or pharmaceutically acceptable salts thereof can be used as an antagonist of CCR5 in preparing medicaments for treating diseases mediated by CCR5, particularly HIV infection, asthma, rheumatoid arthritis, autoimmune diseases and chronic obstructive pulmonary diseases (COPD). | 2011-10-13 |
20110251193 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES - Novel classes of 1,2-benzisothiazolinone and isoindolinone compounds and compositions are disclosed. These compounds and compositions are useful in treating, preventing, and/or ameliorating viral, yeast, and fungal infections such as, for example, Hepatitis C Virus, Flavivirus infections, | 2011-10-13 |
20110251194 | ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The disclosure concerns heterobicyclic compounds of general formula (I) and acid addition salts, hydrates and solvates thereof, as well as enantiomers, diastereoisomers and mixtures thereof. Methods for preparing the compounds, pharmaceutical compositions, and methods of treatment also are disclosed. | 2011-10-13 |
20110251195 | ADRB2 GENE POLYMORPHISM ASSOCIATED WITH INTRAOCULAR PRESSURE RESPONSE TO TOPICAL BETA-BLOCKERS - The invention provides a single nucleotide polymorphism (SNP) rs1042714 in the human ADRB2 gene (Gln27Glu) associated with a clinically meaningful reduction in intraocular pressure (IOP) in a human following treatment with a topical beta-blocker. Nucleic acids comprising the SNP are used to screen glaucoma-afflicted individuals to thereby provide an improved method for genotype-based prescribing of beta-blockers in glaucoma management. | 2011-10-13 |
20110251196 | Modulators of G Protein-Coupled Receptor 88 - The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88. | 2011-10-13 |
20110251197 | LYSOSOMOTROPIC INHIBITORS OF ACID CERAMIDASE - The presently disclosed subject matter provides compounds of the formula, formula (Ia): and pharmaceutically acceptable salts thereof, wherein R | 2011-10-13 |
20110251198 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF - Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine. | 2011-10-13 |
20110251199 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE - The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I | 2011-10-13 |
20110251200 | ARYL GUANIDINE F1F0-ATPASE INHIBITORS AND RELATED METHODS - The invention provides to a family of aryl guanidine-based F | 2011-10-13 |
20110251201 | Sustained release intraocular implants and methods for preventing retinal dysfunction - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like. | 2011-10-13 |
20110251202 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors - The invention relates to novel organic compounds of formula (I) | 2011-10-13 |
20110251203 | USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS - The present invention pertains “to the use of a PKC inhibitor in the manufacture of a medicament in the treatment or prevention of diabetic complications, where in the PKC inhibitor is one of 3-(1.H.-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione, 3-(1.H.-indol-3-yl)-4-[2-(piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione, 3-[3-(4,7-Diaza-spiro [2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof. | 2011-10-13 |
20110251204 | Modulators of G Protein-Coupled Receptor 88 - The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88. | 2011-10-13 |
20110251205 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST - The present invention relates to compounds of formula (I) | 2011-10-13 |
20110251206 | Squaramide derivatives as CXCR2 antagonist - The present invention relates to compounds of formula (I) | 2011-10-13 |
20110251207 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 2011-10-13 |
20110251208 | PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY - The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca | 2011-10-13 |
20110251209 | COMPOUNDS FOR TREATING PARASITIC DISEASE - A compound, particularly an antimalarial compound, according to formula I: | 2011-10-13 |
20110251210 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY - The disclosure provides modified chloroquine compounds having single ring or fused ring moieties. Also provided are pharmaceutical compositions comprising such compounds, methods of using such compounds to inhibit or treat diseases or conditions caused by chloroquine-resistant (CQ | 2011-10-13 |
20110251211 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS - A method for treating a subject having an inflammatory or auto-immune disease with a substituted isoxazolo pyridinone. Also, a method for administering a substituted isoxazolo pyridinone to a cell to retain or increase glucocorticoid receptor transrepression activity with only minimal glucocorticoid receptor transactivation activity. | 2011-10-13 |
20110251212 | PIPERAZINE DERIVATIVES - A compound which specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist is provided. | 2011-10-13 |
20110251213 | Cosmetic Use of 1-Aroyl-N-(2-oxo-3-piperidinyl)-2-Piperazine Carbomamides and Related Compounds - Cosmetic compositions comprising 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The 1-aroyl-N-(2-oxo-3-piperidinyl)-2-piperazine carboxamides are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging. | 2011-10-13 |
20110251214 | MONOHYDRATE OF PARDOPRUNOX - This invention relates to a process for the preparation of 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride, a partial dopamine-D | 2011-10-13 |
20110251215 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS - The present invention relates to macrocyclic compounds of Formula I: | 2011-10-13 |
20110251216 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 - The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in cancer (e.g., prostate cancer, breast cancer, other solid tumors, multiple myeloma). | 2011-10-13 |
20110251217 | SUBSTITUTED PURINYL-PYRAZOL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel substituted purinyl-pyrazol derivatives of formula (I) and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 2011-10-13 |
20110251218 | NOVEL COMPOUNDS - The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione of Formula (A) or a pharmaceutically acceptable salt thereof: | 2011-10-13 |
20110251219 | TREATMENT FOR GLOMERULONEPHRITIS WITH 2-[4-(7-ETHYL-5H-PYRROLO[2,3-B]PYRAZIN-6-YL)PHENYL]PROPAN-2-OL - A treatment for glomerulonephritis, and other renal dysfunctions using a compound of Formula I is disclosed. | 2011-10-13 |
20110251220 | Pharmaceutical compositions comprising gamma secretase modulators - The present invention relates to pharmaceutical compositions comprising gamma secretase modulators as well as to the use of gamma secretase modulators for treating renal disorders, cancer, neurodegenerative disorders as well as related disorders. | 2011-10-13 |
20110251221 | PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS - Novel compounds of structure Formula I: | 2011-10-13 |
20110251222 | SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE - The invention relates to sulphone-substituted anilinopyrimidine derivatives of the formula (I), | 2011-10-13 |
20110251223 | CGRP Receptor Antagonists - The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). | 2011-10-13 |
20110251224 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS - This invention is directed to spiro-oxindole compounds of formula (I): | 2011-10-13 |
20110251225 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): | 2011-10-13 |
20110251226 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES - The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) | 2011-10-13 |